



The Optimizer[®] Smart Mini is a minimally invasive, implantable device that delivers a proprietary therapy called *CCM*[®] to patients with chronic heart failure. *CCM*[®] therapy has been designed to improve overall heart function, and quality of life for patients.

61.3 mm

WHO For patients with:

- LVEF 25-45%
- NYHA Class III
- Symptomatic despite guideline directed medical therapy
- Not indicated for Cardiac
 Resynchronization Therapy

WHAT

The Optimizer® Smart Mini delivers *CCM*® therapy, which:

- Applies non-excitatory electrical signals to the RV septum during the absolute refractory period using standard leads
- Improves NYHA functional status, 6-minute hall walk distance and QoL status
- Has rapid, intermediate and long-term effects







Inter e

HOURS TO WEEKS

- Local electrotonic
 spread of signal
 program
 failure to
- Rapid phosphorylation of key proteins

MINUTES TO HOURS

- Improved calcium cycling and contractile force
- No increased myocardial oxygen consumption
- Shift of gene program from heart failure to normal
- Local effects improve contraction at global level

Long-Term



WEEKS TO MONTHS

• Beneficial effect on global ventricular properties

HOW

The Optimizer[®] Smart Mini delivers *CCM*[®] therapy in five one-hour therapy delivery phases separated by 3.8-hour rest periods¹

- Device recharged weekly for one-hour period
- Device longevity 20 years



24 Hour Therapy Clock

Patient EKG During **CCM**® Therapy



Optimizer[®] Smart Mini System and its predecessors have been implanted in over 7,000 patients and is currently available in the U.S., Europe, China, Brazil, India and more than 40 other countries around the world.

For more information, visit our website at **ImpulseDynamics.com** or contact us at 856–642–9933.

Indications for Use: The Optimizer® Smart Mini System, which delivers **CCM**® therapy, is indicated to improve 6 minute hall walk, quality of life, and functional status of NYHA Class III heart failure patients who remain symptomatic despite guideline directed medical therapy, are not indicated for CRT, and have a left ventricular ejection fraction ranging from 25% to 45%.



¹ Campbell CM, Kahwash R, & Abraham WT. Optimizer Smart in the treatment of moderate-to-severe chronic heart failure. FutureCardiol. 16(1), 13–25 (2020)

© Impulse Dynamics 2022. All rights reserved.

ID-A292-US Rev 01